EDSA
Edesa Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$2.78
+8.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.64
From 52W high−84.78%
Volume25214.00
Market cap$26.80M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.64
From 52W high
−84.78%
Volume
25214.00
Market cap
$26.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
P/E (TTM)
—
RSI (14)
29.8
MomentumView details →
1D Return
+8.17%
YTD Return
+91.55%
SummaryUpdated Jun 1, 2026
Edesa Biotech, Inc. (NASDAQ:EDSA) is a Canadian biopharmaceutical company founded in 2015 and headquartered in Markham, Ontario. The company went public in 2010 and focuses on acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases. As a clinical-stage biotechnology firm, Edesa operates without generating revenue from product sales, instead relying on funding to advance its drug candidates through various phases of clinical trials toward potential regulatory approval and commercialization.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration cleared Edesa Biotech's IND application for a Phase 2 study of EB06 in vitiligo, enabling recruitment in the United States.5d agoEdesa Biotech announced the commencement of an underwritten public offering of its common shares (or pre-funded warrants in lieu thereof) and accompanying common share warrants, with a 30-day option for underwriters to purchase up to 15% additional shares and warrants.61d ago